Physician profile
Muhammad Ali
NPI 1427248608
$10,416.70
in general payments reported to CMS, 2019-2025
38 companies · $2,801 in 2025
The $2,801 reported for 2025 was more than what 86% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,079 · 2020: $523 · 2021: $1,118 · 2022: $1,886 · 2023: $1,451 · 2024: $1,559 · 2025: $2,801.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,786 · Education: $24.67.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,785.76 |
| Education | $24.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,064.63 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,509.86 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $912.29 | 2020-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $499.72 | 2019-2025 | Gattex, Entyvio, Eohilia |
| Pfizer INC. | $413.75 | 2019-2025 | |
| Genzyme Corporation | $295.53 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $207.08 | 2023-2025 | Voquezna |
| Allergan, INC. | $207.02 | 2019-2020 | |
| Lilly USA, LLC | $204.63 | 2024-2025 | Omvoh |
| Qol Medical, LLC | $200.27 | 2019-2025 | Sucraid, Sucraid |
| Ardelyx, INC. | $172.48 | 2022-2023 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $170.88 | 2019-2023 | Linzess |
| Madrigal Pharmaceuticals | $168.28 | 2024-2025 | Rezdiffra, Resmetirom |
| Intercept Pharmaceuticals, INC. | $155.93 | 2019-2024 | |
| Aimmune Therapeutics, INC. | $127.68 | 2024 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $126.37 | 2021-2023 | Zeposia |
| Boston Scientific Corporation | $120.97 | 2025 | General - Pain Management |
| Ipsen Biopharmaceuticals, INC | $111.74 | 2024-2025 | Iqirvo |
| Echosens North America, INC. | $78.44 | 2025 | Fibroscan |
| Evoke Pharma, INC. | $72.64 | 2021-2025 | |
| Ferring Pharmaceuticals INC. | $61.93 | 2019-2021 | |
| Gilead Sciences, INC. | $54.77 | 2019-2020 | |
| Braintree Laboratories, INC. | $53.91 | 2021-2025 | Suflave, Sutab |
| Medtronic Vascular, INC. | $52.29 | 2019 | |
| Celltrion USA INC. | $46.77 | 2023-2025 | Zymfentra, Vegzelma |
| Alfasigma USA, INC. | $46.62 | 2020 | |
| Nestle Healthcare Nutrition INC. | $39.47 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $38.05 | 2019-2021 | |
| Micro-Tech Endoscopy USA, INC. | $37.89 | 2021-2025 | Forceps |
| Ucb, INC. | $37.55 | 2019-2020 | |
| Daiichi Sankyo INC. | $35.92 | 2019-2020 | |
| Cranial Technologies, INC | $19.67 | 2025 | Doc Band |
| Olympus America INC. | $19.31 | 2021 | |
| Sandoz INC. | $14.34 | 2023 | |
| Ethicon US, LLC | $13.21 | 2021 | |
| Redhill Biopharma INC. | $12.51 | 2022 | |
| Amgen INC. | $12.30 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$85,307.84 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.